

Second Quarter

# 2023 Financial Results



Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world.



Sustained underlying growth



Pipeline and portfolio progress



Expansive research efforts



“We continue to make great progress as we advance our broad and deep pipeline, raise the bar of innovation, and bring forward leading-edge science to save and improve lives around the world. We delivered robust underlying growth during the second quarter and are well positioned to achieve strong full-year results. I am proud of our talented, diverse and dedicated global team that continues to focus on creating value for patients and all our stakeholders now and well into the future.”

Rob Davis  
Chairman and Chief Executive Officer, MSD

Q2 performance reflects sustained underlying growth

Q2 WORLDWIDE SALES

\$15.0B

GAAP LOSS PER SHARE\*

\$2.35

NON-GAAP LOSS PER SHARE\*

\$2.06

\*GAAP and non-GAAP loss per share include a one-time charge of \$4.02 per share for the acquisition of Prometheus Biosciences, Inc.

Updated 2023 sales outlook underscores ongoing demand

2023 FINANCIAL OUTLOOK

\$58.6B  
to  
\$59.6B

2023 EXPECTED NON-GAAP EPS

\$2.95  
to  
\$3.05

Sales

KEYTRUDA<sup>®</sup>  
(pembrolizumab) Injection 100 mg

\$6.3B  
19% Growth

GARDASIL<sup>®</sup>  
(Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant)

GARDASIL<sup>®</sup> 9  
(Human Papillomavirus 9-valent Vaccine, Recombinant)

\$2.5B  
47% Growth

MSD  
Animal Health

\$1.5B  
1% Decline



Q2  
2023  
Financial Results